NCT06550336View on ClinicalTrials.gov

A Clinical Study Assessing the Efficacy of Chidamide for CD30-positive Peripheral T-cell Lymphoma (PTCL).

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

December 30, 2027

Study Completion Date

December 30, 2027

Conditions
Peripheral T Cell Lymphoma
Interventions
DRUG

Chidamide

20 mg (4 tablets) twice a week, specifically on days 1, 4, 8, 11, 15, 18, 22, and 25.Each 4-week period constitutes one treatment cycle.

Trial Locations (1)

130021

The First Bethune Hospital of Jilin University, Changchun

All Listed Sponsors
lead

The First Hospital of Jilin University

OTHER

NCT06550336 - A Clinical Study Assessing the Efficacy of Chidamide for CD30-positive Peripheral T-cell Lymphoma (PTCL). | Biotech Hunter | Biotech Hunter